Indaptus Therapeutics, Inc. Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount
Indaptus Therapeutics, Inc. (INDP) reported Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount of $3.80 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets
us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount · last filed 2026-03-17
- Indaptus Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2025 was $3.80M, a 52.00% increase from fiscal 2024.
- Indaptus Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2024 was $2.50M, a 0.00% change from fiscal 2023.
- Indaptus Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2023 was $2.50M, a 66.67% increase from fiscal 2022.
- Indaptus Therapeutics, Inc. valuation allowance, deferred tax asset, increase (decrease), amount for fiscal 2022 was $1.50M, a 97.07% decline from fiscal 2021.
| Period end | Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount 12 month |
|---|---|
| 2025-12-31 | $3.80M 10-K · filed 2026-03-17 |
| 2024-12-31 | $2.50M 10-K · filed 2026-03-17 |
| 2023-12-31 | $2.50M 10-K · filed 2025-03-13 |
| 2022-12-31 | $1.50M 10-K · filed 2024-03-13 |
| 2021-12-31 | $51.20M 10-K · filed 2023-03-17 |
| 2020-12-31 | $1.00M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |